OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects
Nicolas Villain, Vincent Planche, Raymond Levy
Revue Neurologique (2022) Vol. 178, Iss. 10, pp. 1011-1030
Open Access | Times Cited: 64
Nicolas Villain, Vincent Planche, Raymond Levy
Revue Neurologique (2022) Vol. 178, Iss. 10, pp. 1011-1030
Open Access | Times Cited: 64
Showing 1-25 of 64 citing articles:
Alzheimer's disease: From immunotherapy to immunoprevention
Mathias Jucker, Lary C. Walker
Cell (2023) Vol. 186, Iss. 20, pp. 4260-4270
Open Access | Times Cited: 123
Mathias Jucker, Lary C. Walker
Cell (2023) Vol. 186, Iss. 20, pp. 4260-4270
Open Access | Times Cited: 123
The amyloid cascade hypothesis: an updated critical review
Kasper P. Kepp, Nikolaos K. Robakis, Poul Flemming Høilund‐Carlsen, et al.
Brain (2023) Vol. 146, Iss. 10, pp. 3969-3990
Open Access | Times Cited: 106
Kasper P. Kepp, Nikolaos K. Robakis, Poul Flemming Høilund‐Carlsen, et al.
Brain (2023) Vol. 146, Iss. 10, pp. 3969-3990
Open Access | Times Cited: 106
Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis
Danko Jeremic, Juan D. Navarro‐López, Lydia Jiménez‐Díaz
Ageing Research Reviews (2023) Vol. 90, pp. 102012-102012
Closed Access | Times Cited: 41
Danko Jeremic, Juan D. Navarro‐López, Lydia Jiménez‐Díaz
Ageing Research Reviews (2023) Vol. 90, pp. 102012-102012
Closed Access | Times Cited: 41
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Qiuyang Zheng, Xin Wang
Protein & Cell (2024)
Open Access | Times Cited: 19
Qiuyang Zheng, Xin Wang
Protein & Cell (2024)
Open Access | Times Cited: 19
Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis
Yue Qiao, Jian Gu, Miao Yu, et al.
CNS Drugs (2024) Vol. 38, Iss. 3, pp. 169-192
Closed Access | Times Cited: 15
Yue Qiao, Jian Gu, Miao Yu, et al.
CNS Drugs (2024) Vol. 38, Iss. 3, pp. 169-192
Closed Access | Times Cited: 15
Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease
Kathy Liu, Nicolas Villain, Scott Ayton, et al.
Brain Communications (2023) Vol. 5, Iss. 3
Open Access | Times Cited: 36
Kathy Liu, Nicolas Villain, Scott Ayton, et al.
Brain Communications (2023) Vol. 5, Iss. 3
Open Access | Times Cited: 36
Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development
Rouen Brockmann, Ioanna Nixon, Bryan L. Love, et al.
The Lancet Regional Health - Americas (2023) Vol. 20, pp. 100467-100467
Open Access | Times Cited: 31
Rouen Brockmann, Ioanna Nixon, Bryan L. Love, et al.
The Lancet Regional Health - Americas (2023) Vol. 20, pp. 100467-100467
Open Access | Times Cited: 31
Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals
Wagner S. Brum, Nicholas J. Ashton, Joel Simrén, et al.
Alzheimer s & Dementia (2023) Vol. 20, Iss. 2, pp. 1284-1297
Open Access | Times Cited: 28
Wagner S. Brum, Nicholas J. Ashton, Joel Simrén, et al.
Alzheimer s & Dementia (2023) Vol. 20, Iss. 2, pp. 1284-1297
Open Access | Times Cited: 28
Mesenchymal and Neural Stem Cell-Derived Exosomes in Treating Alzheimer’s Disease
Hongmin Wang, Christa C. Huber, Xiaoping Li
Bioengineering (2023) Vol. 10, Iss. 2, pp. 253-253
Open Access | Times Cited: 22
Hongmin Wang, Christa C. Huber, Xiaoping Li
Bioengineering (2023) Vol. 10, Iss. 2, pp. 253-253
Open Access | Times Cited: 22
Glymphatic system dysfunction in neurodegenerative diseases
Natalie Beschörner, Maiken Nedergaard
Current Opinion in Neurology (2024) Vol. 37, Iss. 2, pp. 182-188
Closed Access | Times Cited: 8
Natalie Beschörner, Maiken Nedergaard
Current Opinion in Neurology (2024) Vol. 37, Iss. 2, pp. 182-188
Closed Access | Times Cited: 8
The effectiveness and value of lecanemab for early Alzheimer disease: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
Abigail C. Wright, Grace A. Lin, Melanie D. Whittington, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 9, pp. 1078-1083
Open Access | Times Cited: 21
Abigail C. Wright, Grace A. Lin, Melanie D. Whittington, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 9, pp. 1078-1083
Open Access | Times Cited: 21
Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?
Vincent Planche, Nicolas Villain
JAMA Neurology (2023) Vol. 80, Iss. 7, pp. 659-659
Open Access | Times Cited: 17
Vincent Planche, Nicolas Villain
JAMA Neurology (2023) Vol. 80, Iss. 7, pp. 659-659
Open Access | Times Cited: 17
Targeting epigenetics: A novel promise for Alzheimer’s disease treatment
Danko Jeremic, Lydia Jiménez‐Díaz, Juan D. Navarro‐López
Ageing Research Reviews (2023) Vol. 90, pp. 102003-102003
Closed Access | Times Cited: 17
Danko Jeremic, Lydia Jiménez‐Díaz, Juan D. Navarro‐López
Ageing Research Reviews (2023) Vol. 90, pp. 102003-102003
Closed Access | Times Cited: 17
Alzheimer’s Disease Treatment: The Search for a Breakthrough
Allison B. Reiss, Dalia Muhieddine, Berlin Jacob, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1084-1084
Open Access | Times Cited: 16
Allison B. Reiss, Dalia Muhieddine, Berlin Jacob, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1084-1084
Open Access | Times Cited: 16
Bayesian meta‐analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease
Stefan Teipel, Anna G. M. Temp, Michael W. Lutz
Alzheimer s & Dementia Translational Research & Clinical Interventions (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Stefan Teipel, Anna G. M. Temp, Michael W. Lutz
Alzheimer s & Dementia Translational Research & Clinical Interventions (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Anatomical MRI staging of frontotemporal dementia variants
Vincent Planche, Boris Mansencal, José V. Manjón, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 8, pp. 3283-3294
Open Access | Times Cited: 15
Vincent Planche, Boris Mansencal, José V. Manjón, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 8, pp. 3283-3294
Open Access | Times Cited: 15
People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare
Karin Wahlberg, Bengt Winblad, Amanda Cole, et al.
Journal of Internal Medicine (2023) Vol. 295, Iss. 3, pp. 281-291
Open Access | Times Cited: 14
Karin Wahlberg, Bengt Winblad, Amanda Cole, et al.
Journal of Internal Medicine (2023) Vol. 295, Iss. 3, pp. 281-291
Open Access | Times Cited: 14
The iceberg of dementia risk: empirical and conceptual arguments in favor of structural interventions for brain health
Timothy Daly
Cerebral Circulation - Cognition and Behavior (2023) Vol. 6, pp. 100193-100193
Open Access | Times Cited: 13
Timothy Daly
Cerebral Circulation - Cognition and Behavior (2023) Vol. 6, pp. 100193-100193
Open Access | Times Cited: 13
Functionalized nanoparticles to deliver nucleic acids to the brain for the treatment of Alzheimer’s disease
Chinenye Edith Muolokwu, Bivek Chaulagain, Avinash Gothwal, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Chinenye Edith Muolokwu, Bivek Chaulagain, Avinash Gothwal, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Successes and failures: the latest advances in the clinical development of amyloid-β-targeting monoclonal antibodies for treating Alzheimer’s disease
Francesco Panza, Vittorio Dibello, Rodolfo Sardone, et al.
Expert Opinion on Biological Therapy (2025)
Closed Access
Francesco Panza, Vittorio Dibello, Rodolfo Sardone, et al.
Expert Opinion on Biological Therapy (2025)
Closed Access
Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics
Nicolas Villain, Vincent Planche, Matthieu Lilamand, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100094-100094
Open Access
Nicolas Villain, Vincent Planche, Matthieu Lilamand, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100094-100094
Open Access
Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective
Amy Bobbins, Miranda Davies, Elizabeth Lynn, et al.
British Journal of Clinical Pharmacology (2025)
Open Access
Amy Bobbins, Miranda Davies, Elizabeth Lynn, et al.
British Journal of Clinical Pharmacology (2025)
Open Access
Utilizing Hyperbaric Oxygen Therapy to Improve Cognitive Function in Patients With Alzheimer's Disease by Activating Autophagy-Related Signaling Pathways
Biao Li, Hongmei Li, Hui Chen, et al.
Physiological Research (2025), Iss. 1/2025, pp. 141-147
Open Access
Biao Li, Hongmei Li, Hui Chen, et al.
Physiological Research (2025), Iss. 1/2025, pp. 141-147
Open Access
Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer’s disease: A systematic review and meta-analysis
Reina Tonegawa‐Kuji, Yuan Hou, Bo Hu, et al.
PLoS Medicine (2025) Vol. 22, Iss. 3, pp. e1004568-e1004568
Open Access
Reina Tonegawa‐Kuji, Yuan Hou, Bo Hu, et al.
PLoS Medicine (2025) Vol. 22, Iss. 3, pp. e1004568-e1004568
Open Access
Alzheimer’s Disease: Engaging with an Unstable Category
Timothy Daly, Lara Keuck
Springer eBooks (2024), pp. 1-24
Closed Access | Times Cited: 4
Timothy Daly, Lara Keuck
Springer eBooks (2024), pp. 1-24
Closed Access | Times Cited: 4
